Literature DB >> 34362009

Air Pollutants' Concentrations Are Associated with Increased Number of RSV Hospitalizations in Polish Children.

August Wrotek1,2, Artur Badyda3,4, Piotr O Czechowski5, Tomasz Owczarek5, Piotr Dąbrowiecki4,6, Teresa Jackowska1,2.   

Abstract

Respiratory syncytial virus (RSV) contributes significantly to pediatric hospitalizations. An association between air pollution and an increased number of RSV cases has been suggested. We sought to evaluate the short-term impact of air pollutants on RSV hospitalizations in Polish children in the period 2010-2019. Daily concentrations of PM10 and PM2.5 (particulate matter with an aerodynamic diameter less than or equal to 10 μm and 2.5 μm, respectively) and nitrogen dioxide (NO2) were analyzed in general regression models (GRM) to establish their influence and full interaction scheme. Significant seasonal and annual periodicity among 53,221 hospitalizations was observed; finally, data from the 2012-2019 RSV high-risk seasons created models for seven agglomerations. The addition of PM2.5, PM10, and NO2 to the basic model for RSV seasonality explained 23% (4.9-31%, univariate model) to 31.4% (8.4-31%, multivariate model) of the variance in RSV hospitalizations. A 10 μg/m3 increase in PM2.5, PM10, and NO2 concentrations was associated with 0.134 (0.087-0.16), 0.097 (0.031-0.087), and 0.212 (0.04-0.29) average increases in hospitalizations, respectively. In the multivariate models, PM2.5, PM10, and NO2 alone, as well as PM2.5-NO2, PM2.5-PM10, and PM10-NO2 interactions, were associated with hospitalizations in some of the locations, while the metaregression showed statistically significant interactions between each of the pollutants, and between the pollutants and the year of the study. The inclusion of PM2.5, PM10, and NO2 in GRM explains a significant number of RSV hospitalizations. The pollutants act alone and interact together in a varied manner. Reducing air contamination might decrease the costs of hospital healthcare.

Entities:  

Keywords:  air pollution; bronchiolitis; children; hospitalization; nitrogen dioxide; particulate matter; pneumonia; respiratory syncytial virus

Year:  2021        PMID: 34362009     DOI: 10.3390/jcm10153224

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

1.  Changes in Air-Pollution-Related Information-Seeking Behaviour during the COVID-19 Pandemic in Poland.

Authors:  Wojciech Nazar; Marek Niedoszytko
Journal:  Int J Environ Res Public Health       Date:  2022-05-05       Impact factor: 4.614

2.  Influence of Selected Air Pollutants on Mortality and Pneumonia Burden in Three Polish Cities over the Years 2011-2018.

Authors:  Piotr Dąbrowiecki; Artur Badyda; Andrzej Chciałowski; Piotr Oskar Czechowski; August Wrotek
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

3.  The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland.

Authors:  Piotr Rzymski; Barbara Poniedziałek; Joanna Rosińska; Magdalena Rogalska; Dorota Zarębska-Michaluk; Marta Rorat; Anna Moniuszko-Malinowska; Beata Lorenc; Dorota Kozielewicz; Anna Piekarska; Katarzyna Sikorska; Anna Dworzańska; Beata Bolewska; Grzegorz Angielski; Justyna Kowalska; Regina Podlasin; Barbara Oczko-Grzesik; Włodzimierz Mazur; Aleksandra Szymczak; Robert Flisiak
Journal:  Environ Pollut       Date:  2022-05-14       Impact factor: 9.988

Review 4.  Air Pollution in Poland: A 2022 Narrative Review with Focus on Respiratory Diseases.

Authors:  Wojciech Nazar; Marek Niedoszytko
Journal:  Int J Environ Res Public Health       Date:  2022-01-14       Impact factor: 3.390

5.  Long-Term PM2.5 Exposure Is Associated with Symptoms of Acute Respiratory Infections among Children under Five Years of Age in Kenya, 2014.

Authors:  Peter S Larson; Leon Espira; Bailey E Glenn; Miles C Larson; Christopher S Crowe; Seoyeon Jang; Marie S O'Neill
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.